Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21012023 | 1.00 | ESR1 (0.58) | ESR1PGRKDM4EALDH1A1MAPT | |
| SCHEMBL21011957 | 0.88 | ESR1 (0.56) | ESR1PGRKDM4EALDH1A1MAPT | |
| SCHEMBL21012130 | 0.87 | ESR1 (0.73) | ESR1 | |
| SCHEMBL23793738 | 0.87 | ESR1 (0.73) | ESR1 | |
| Palazestrant SCHEMBL24885107 | 0.84 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL23280512 | 0.84 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL20528170 | 0.84 | ESR1 (0.78) | ESR1PGR | |
| Palazestrant SCHEMBL30128723 | 0.84 | ESR1 (0.78) | ESR1PGR | |
| SCHEMBL24443798 | 0.82 | ESR1 (0.54) | ESR1PGRKDM4EALDH1A1MAPT | |
| SCHEMBL21012045 | 0.82 | ESR1 (0.61) | ESR1KDM4EALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076626-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024015506-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023091550-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023283329-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2021178846-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |